-
Phathom Pharmaceuticals NASDAQ:PHAT Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.
Location: | Website: www.phathompharma.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
662.3M
Cash
334.7M
Avg Qtr Burn
-61.78M
Short % of Float
26.82%
Insider Ownership
7.73%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VOQUEZNA (Vonoprazan)(Potassium competitive acid blocker) Details Intestinal infection, Gastroesophageal reflux disease, Esophagitis | Approved Quarterly sales | |
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease | Approved Quarterly sales | |
VOQUEZNA (Vonoprazan) (Potassium competitive acid blocker) Details Bacterial infection | Approved Quarterly sales | |
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease | Phase 3 Initiation | |
VOQUEZNA® (Vonoprazan)(potassium competitive acid blocker) Details Eosinophilic Esophagitis | Phase 2 Initiation |